Clinical Trial Update: A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma

View source ↗

Summary

A long-term safety study in Brazilian patients with spinal muscular atrophy treated with Zolgensma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Zolgensma (onasemnogene abeparvovec)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Spinal Muscular Atrophies | Status: RECRUITING